- Home
- KRUS vs GERN Comparison
KRUS vs GERN Comparison
Compare KRUS & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KRUS
- GERN
- Stock Information
- Founded
- KRUS 2008
- GERN 1990
- Country
- KRUS United States
- GERN United States
- Employees
- KRUS N/A
- GERN N/A
- Industry
- KRUS Restaurants
- GERN Biotechnology: Pharmaceutical Preparations
- Sector
- KRUS Consumer Discretionary
- GERN Health Care
- Exchange
- KRUS Nasdaq
- GERN Nasdaq
- Market Cap
- KRUS 990.5M
- GERN 974.5M
- IPO Year
- KRUS 2019
- GERN 1996
- Fundamental
- Price
- KRUS $78.94
- GERN $1.25
- Analyst Decision
- KRUS Buy
- GERN Buy
- Analyst Count
- KRUS 9
- GERN 8
- Target Price
- KRUS $94.56
- GERN $3.71
- AVG Volume (30 Days)
- KRUS 350.9K
- GERN 9.1M
- Earning Date
- KRUS 07-08-2025
- GERN 08-07-2025
- Dividend Yield
- KRUS N/A
- GERN N/A
- EPS Growth
- KRUS N/A
- GERN N/A
- EPS
- KRUS N/A
- GERN N/A
- Revenue
- KRUS $269,327,000.00
- GERN $116,293,000.00
- Revenue This Year
- KRUS $20.29
- GERN $161.44
- Revenue Next Year
- KRUS $19.75
- GERN $53.06
- P/E Ratio
- KRUS N/A
- GERN N/A
- Revenue Growth
- KRUS 18.76
- GERN 22264.04
- 52 Week Low
- KRUS $40.03
- GERN $1.17
- 52 Week High
- KRUS $110.66
- GERN $4.89
- Technical
- Relative Strength Index (RSI)
- KRUS 50.81
- GERN 41.94
- Support Level
- KRUS $71.32
- GERN $1.25
- Resistance Level
- KRUS $76.85
- GERN $1.48
- Average True Range (ATR)
- KRUS 4.83
- GERN 0.08
- MACD
- KRUS -1.32
- GERN -0.01
- Stochastic Oscillator
- KRUS 32.44
- GERN 22.92
About KRUS Kura Sushi USA Inc.
Kura Sushi USA Inc is a technology-enabled restaurant concept serving authentic Japanese cuisine through an engaging revolving sushi service model. The company operates a chain of sushi restaurants across the United States serving freshly prepared Japanese cuisine using high-quality ingredients that are free from artificial seasonings, sweeteners, colorings, and preservatives. It offers several dishes, including Dashi Olive Salmon, Tomago, Sweet Shrimp, Tuna, Garlic Tuna Steak, and Salmon, among others.
About GERN Geron Corporation
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.